CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Damora Therapeutics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date: March 19, 2026 |
|
By: |
/s/ Sherwin Sattarzadeh |
|
|
|
Sherwin Sattarzadeh |
|
|
|
Chief Operating Officer (Principal Executive Officer) |
|
|
|
|
Date: March 19, 2026 |
|
By: |
/s/ Lori Firmani |
|
|
|
Lori Firmani |
|
|
|
Chief Financial Officer (Principal Financial and Accounting Officer) |